Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results

Key Points

• Nautilus Biotechnology exceeded quarterly expectations: The company reported a loss of $0.12 per share, beating the consensus estimate of a $0.14 loss, while revenue reached $0.23 million versus the $0.21 million forecast.
• Shares opened at $2.44, with a market capitalization of approximately $310.5 million. The stock has traded between $0.84 and $4.31 over the past year.
• Analyst sentiment is generally positive, with a “Moderate Buy” consensus and an average price target of $3.83, although ratings range from Strong Buy to Sell.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) posted its earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02, FiscalAI reports. The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.21 million.

Nautilus Biotechnology Price Performance

Shares of NASDAQ:NAUT opened at $2.44 on Tuesday. The company has a market capitalization of $310.49 million, a price-to-earnings ratio of -5.42 and a beta of 0.73. The business's 50-day moving average is $1.42 and its 200-day moving average is $2.09. Nautilus Biotechnology has a 1 year low of $0.84 and a 1 year high of $4.31.

Analyst Ratings Changes

A number of research firms recently commented on NAUT. Weiss Ratings cut shares of Nautilus Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, August 5th. Zacks Research raised Nautilus Biotechnology to a "hold" rating in a research report on Wednesday, September 30th. Roth Capital began coverage on shares of Nautilus Biotechnology in a research note on Tuesday, September 29th. They issued a "buy" rating and a $3.50 target price for the company. Finally, Leerink Partners began coverage on shares of Nautilus Biotechnology in a report on Wednesday, September 9th. They issued an "outperform" rating and a $4.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $3.83.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company's principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.